Loading
A phase 3 trial of Capecitabine, Floxuridine and Oxaliplatin in Colorectal cancer and Metastatic cancer, run by NSABP Foundation Inc, recorded as terminated on the registry.
Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer is a phase 3 interventional study registered as NCT00268463 by NSABP Foundation Inc, with 22 participants recorded, started 2006-01 and due to reach its primary completion in 2008-06. Interventions recorded: capecitabine, floxuridine, oxaliplatin. Conditions recorded: Colorectal Cancer, Metastatic Cancer.
Linked to the drug Floxuridine because the registry names it among its interventions and Colorectal cancer and Metastatic cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Floxuridine, Oxaliplatin, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Colorectal cancer and the tag pipeline.
Shares Floxuridine, Oxaliplatin, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.